SCHEMBL13101490

SCHEMBL13101490

CN1CCNCCN1C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSK P43235 1/20 0.42
USP2 O75604 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAPK1 P28482 1/20 0.35
NR1H2 P55055 1/20 0.35
CHRM2 P08172 1/20 0.34
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34
HPGD P15428 1/20 0.34
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
RECQL P46063 1/20 0.33
EPHX1 P07099 1/20 0.33
PARP1 P09874 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
PREP P48147 1/20 0.31
EPHX2 P34913 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10151471 0.89 CTSK (0.51) CTSKUSP2SMN1; SMN2MAPK1NR1H2
SCHEMBL1190545 0.79 CTSK (0.59) CTSKUSP2SMN1; SMN2NR1H2CHRM2
SCHEMBL13101497 0.79 CTSK (0.41) CTSKUSP2SMN1; SMN2MAPK1NR1H2
SCHEMBL12005408 0.77 USP2 (0.58) USP2SMN1; SMN2MAPK1NR1H2HPGD
SCHEMBL1225127 0.77 USP2 (0.58) USP2SMN1; SMN2MAPK1NR1H2HPGD
SCHEMBL8286 0.77 USP2 (0.58) USP2SMN1; SMN2MAPK1NR1H2HPGD
SCHEMBL587550 0.77 USP2 (0.58) USP2SMN1; SMN2MAPK1NR1H2HPGD
Hydrochloric Acid SCHEMBL4141237 0.76 USP2 (0.56) USP2SMN1; SMN2MAPK1NR1H2HPGD
Ammonia Solution, Strong SCHEMBL18035416 0.76 USP2 (0.56) USP2SMN1; SMN2MAPK1NR1H2HPGD
SCHEMBL132585 0.76 USP2 (0.56) USP2SMN1; SMN2MAPK1NR1H2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8530646-B2 Oxazolidinone derivative having 7-membered hetero ring RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2013-09-10 US disclosed
US-8530646-B2 Oxazolidinone derivative having 7-membered hetero ring RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2013-09-10 US disclosed
US-20100256355-A1 OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING Research Foundation ITSUU Laboratory and Shionogi & Co., Ltd. 2010-10-07 US disclosed
US-20100256355-A1 OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING Research Foundation ITSUU Laboratory and Shionogi & Co., Ltd. 2010-10-07 US disclosed
EP-2233484-A2 Oxazolidinone derivatives having a 7-membered heterocyclic ring Research Foundation Itsuu Laboratory (JP) 2010-09-29 EP disclosed
EP-2208729-A1 OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING Research Foundation Itsuu Laboratory (JP) 2010-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256355-A1 OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING NR0B2, NR0B1, NR2C2 CTSK 4655/4885USP2 3934/4885SMN1; SMN2 2032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.